Varegacestat produced the strongest desmoid tumor shrinkage at 1.2 mg once daily
RINGSIDE phase II gave a clear dose signal in desmoid tumors: the lowest daily regimen, 1.2 mg once daily, delivered the deepest tumor volume reductions and the highest response rate. In a disease defined by relentless local growth and difficult symptom control, an oral gamma-secretase inhibitor that can contract tumor burden without major systemic toxicity has immediate clinical relevance. The study enrolled adults with histologically confirmed desmoid tumors and documented disease progression, a population in which treatment decisions often hinge on balancing symptom relief against the risk of overtreatment.
The randomized component assigned 42 participants in equal numbers to three regimens: 1.2 mg once daily, 2 mg intermittent, and 4 mg intermittent. Safety served as the primary end point, while the secondary end point measured change in tumor volume from baseline to week 16 by blinded independent central review. The design was open-label, but the use of central imaging review strengthened the tumor-volume assessment and reduced the chance that local interpretation would inflate response estimates.
A lower daily dose outperformed the intermittent schedules
The dose comparison was striking. Median tumor volume reduction at week 16 reached -51.91% with 1.2 mg once daily, compared with -15.25% with the 2 mg intermittent schedule and -9.50% with the 4 mg intermittent schedule. Confirmed objective response rates tracked in the same direction: 35.7% for 1.2 mg once daily, 21.4% for 2 mg intermittent, and 21.4% for 4 mg intermittent.
A single sentence captures the practical meaning of those numbers: the most continuous exposure produced the best antitumor effect.
For desmoid tumors, where growth is locally destructive rather than metastatic, depth of shrinkage matters because even modest volume loss can translate into less pain, fewer functional limitations, and less need for morbid surgery. Gamma-secretase inhibition is biologically plausible in this setting because the Notch pathway has been implicated in desmoid tumor pathogenesis, and suppressing that signaling axis may interrupt the proliferative drive that sustains these fibroblastic neoplasms. The trial results fit that model better than the intermittent schedules, suggesting that steady pathway suppression may be more important than higher peak exposure.
Safety was manageable, with no serious treatment-related events
Treatment exposure was substantial. Median varegacestat exposure in the randomized study was 50.5 weeks, with a range of 3.0 to 76.0 weeks. Nearly every participant reported a treatment-related adverse event: 41 of 42 participants, or 97.6%. Grade 3 events occurred in 9 participants, or 21.4%. No serious adverse events were reported, and no grade 4 or 5 events occurred.
Those safety data matter because desmoid tumor therapy is often delivered to patients who are not facing immediate mortality but are living with chronic morbidity. In that context, even a moderately toxic drug can be difficult to justify if the antitumor effect is weak. Here, the adverse-event burden did not erase the benefit signal. The absence of serious adverse events and the lack of grade 4 or 5 toxicity support the view that varegacestat can be administered with a manageable safety profile in this disease setting, even though the nearly universal rate of treatment-related adverse events signals that monitoring will remain necessary.
Open-label extension deepened the response signal
Participants who entered the open-label extension continued on the selected 1.2 mg once-daily dose. Among 29 participants, representing 69% of the randomized cohort, median exposure reached 102.0 weeks, with a range of 3.0 to 169.0 weeks. During that longer treatment period, the median best percent tumor volume change improved to -85.88%, and the confirmed objective response rate rose to 57.1%.
The extension data are clinically important because desmoid tumors often require prolonged treatment before the full benefit becomes apparent. Earlier imaging can underestimate eventual response, especially when a therapy slows biologic activity before maximal size reduction is visible. Longer exposure to a dose that already showed the strongest early effect produced deeper contraction over time, reinforcing the impression that the 1.2 mg daily regimen carried the clearest activity signal in the trial.
One finding stands out sharply: the extension cohort nearly doubled its confirmed response rate compared with the randomized 1.2 mg group.
Why the selected dose makes biological and clinical sense
The phase III selection of 1.2 mg once daily followed the pattern established by the randomized comparison and the extension cohort. Rather than favoring intermittent higher doses, the trial favored continuous lower-dose exposure, likely because sustained target engagement is more relevant than intermittent intensity for a pathway-driven soft tissue neoplasm. For clinicians managing desmoid tumors, that choice also aligns with daily oral administration, a format that can be incorporated into long-term outpatient care without infusion infrastructure.
The data do not describe metastatic control, because that is not the central issue in desmoid disease. The key bedside question is whether a patient’s tumor can be reduced enough to relieve pain, preserve function, and avoid escalating local interventions. RINGSIDE answered that question with a meaningful signal in tumor shrinkage and objective response, especially at 1.2 mg once daily.
Phase III will need to confirm durability and patient-centered benefit
Several issues remain clinically relevant as the program advances. The study was small, with 42 participants in the randomized phase, and the randomized treatment period was short relative to the natural history of desmoid tumors. Tumor-volume change is an important marker, but it is still a surrogate for how patients feel and function. Durable benefit, symptom relief, and long-term tolerability will need confirmation in the phase III setting.
Even so, the current trial offers a coherent dose-finding story: 1.2 mg once daily produced the strongest early tumor reduction, the best confirmed response rate among the randomized groups, and deeper responses during extension therapy. For a rare tumor with limited effective options, that is a clinically meaningful result and the basis for selecting the dose that moves forward into phase III.